Dose–response of benazepril on biomarkers of the classical and alternative pathways of the renin–angiotensin–aldosterone system in dogs
暂无分享,去创建一个
J. Mochel | E. Guillot | Joseph S Smith | J. Ward | O. Domenig | Chelsea A. Iennarella-Servantez | Vojtech Gabriel | L. Yuan | Samantha Sotillo
[1] G. Sinagra,et al. [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.
[2] K. Dorman,et al. Retrospective evaluation of a dose‐dependent effect of angiotensin‐converting enzyme inhibitors on long‐term outcome in dogs with cardiac disease , 2021, Journal of Veterinary Internal Medicine.
[3] É. Larouche-Lebel,et al. Effect of angiotensin receptor blockers and angiotensin‐converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease , 2020, Journal of veterinary internal medicine.
[4] Arthur S Slutsky,et al. Human recombinant soluble ACE2 in severe COVID-19 , 2020, The Lancet Respiratory Medicine.
[5] G. Monteith,et al. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation. , 2020, Veterinary journal.
[6] M. Stowasser,et al. Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism. , 2020, Clinical chemistry.
[7] M. Di Marcello,et al. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study. , 2020, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.
[8] M. Tetti,et al. Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. , 2019, Hypertension.
[9] R. Touyz,et al. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure , 2019, Pharmacological Reviews.
[10] P. Solter,et al. Plasma and tissue angiotensin‐converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease , 2019, Journal of veterinary internal medicine.
[11] L. Halsey. The reign of the p-value is over: what alternative analyses could we employ to fill the power vacuum? , 2019, Biology Letters.
[12] J. Häggström,et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs , 2019, Journal of veterinary internal medicine.
[13] M. Danhof,et al. Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation , 2018, bioRxiv.
[14] M. Gyöngyösi,et al. Low- and High-renin Heart Failure Phenotypes with Clinical Implications. , 2018, Clinical chemistry.
[15] A. Hess,et al. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease. , 2017, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.
[16] R. Santos,et al. Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney , 2016, Scientific Reports.
[17] C. Atkins,et al. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs. , 2015, American journal of veterinary research.
[18] M. Murias,et al. Chemistry and pharmacology of Angiotensin-converting enzyme inhibitors. , 2015, Current pharmaceutical design.
[19] D. Curran‐Everett,et al. The fickle P value generates irreproducible results , 2015, Nature Methods.
[20] Y. Pinto,et al. Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2014, European heart journal.
[21] M. Danhof,et al. Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs , 2014, Chronobiology international.
[22] M. Danhof,et al. Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology , 2013, Chronobiology international.
[23] Tiina Heliö,et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.
[24] B. Ploeger,et al. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. , 2013, Journal of veterinary pharmacology and therapeutics.
[25] M. Smolensky,et al. Administration-Time Differences in Effects of Hypertension Medications on Ambulatory Blood Pressure Regulation , 2013, Chronobiology international.
[26] M. Fink,et al. Response to letter from Atkins et al. Capturing the dynamics of systemic Renin‐Angiotensin‐Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs , 2012 .
[27] A. Christopoulos,et al. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. , 2011, Clinical science.
[28] G. Navis,et al. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. , 2011, Current vascular pharmacology.
[29] C. Couto,et al. White-coat effect on systemic blood pressure in retired racing Greyhounds. , 2011, Journal of veterinary internal medicine.
[30] Xiaobai Li,et al. Detection of congestive heart failure in dogs by Doppler echocardiography. , 2010, Journal of veterinary internal medicine.
[31] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[32] R. Fukushima,et al. The effect of angiotensin-converting enzyme inhibitors of left atrial pressure in dogs with mitral valve regurgitation. , 2010, Journal of veterinary internal medicine.
[33] R. Horne,et al. Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. , 2009, Journal of veterinary internal medicine.
[34] T. Walther,et al. Angiotensin-(1–7) and the G Protein-Coupled Receptor Mas Are Key Players in Renal Inflammation , 2009, PloS one.
[35] F. Fyhrquist,et al. Renin‐angiotensin system revisited , 2008, Journal of internal medicine.
[36] J. Stern,et al. Estimation of left ventricular filling pressure by use of Doppler echocardiography in healthy anesthetized dogs subjected to acute volume loading. , 2008, American journal of veterinary research.
[37] R. Hamlin,et al. Estimation of left ventricular filling pressure by Doppler echocardiography in dogs with pacing-induced heart failure. , 2008, Journal of veterinary internal medicine.
[38] T. DeFrancesco,et al. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. , 2007, Journal of the American Veterinary Medical Association.
[39] E. Schiffrin. Effects of Aldosterone on the Vasculature , 2006, Hypertension.
[40] A. Voors,et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. , 2006, International journal of cardiology.
[41] P. Toutain,et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. , 2004, Journal of veterinary pharmacology and therapeutics.
[42] Cathy A. Brown,et al. Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. , 2003, American journal of veterinary research.
[43] S. A. Brown,et al. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats. , 2002, Journal of veterinary pharmacology and therapeutics.
[44] M. Uechi,et al. Dose-dependent inhibition of angiotensin converting enzyme by enalapril in cats. , 2002, The Journal of veterinary medical science.
[45] P. Toutain,et al. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. , 2000, The Journal of pharmacology and experimental therapeutics.
[46] J. Pouchelon. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. , 1999, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.
[47] A. D. Jernigan,et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. , 1998, Journal of the American Veterinary Medical Association.
[48] R. Hamlin,et al. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. , 1998, Journal of veterinary internal medicine.
[49] M. Takahashi,et al. Hemodynamic changes during administration of drugs for mitral regurgitation in dogs. , 1998, The Journal of veterinary medical science.
[50] R. Hamlin,et al. Effects of enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. , 1996, Journal of veterinary internal medicine.
[51] G. Kaiser,et al. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. , 1995, American journal of veterinary research.
[52] J. Woodfield. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. The COVE Study Group. , 1995, Journal of veterinary internal medicine.
[53] D. Sisson,et al. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group. , 1995, Journal of veterinary internal medicine.
[54] R. Dilley,et al. Mineralocorticoids, hypertension, and cardiac fibrosis. , 1994, The Journal of clinical investigation.
[55] R. Carey,et al. Effects of angiotensin converting enzyme inhibition, sodium depletion, calcium, isoproterenol, and angiotensin II on renin secretion by individual renocortical cells. , 1992, Endocrinology.
[56] J. Hall. Control of blood pressure by the renin‐angiotensin‐aldosterone system , 1991, Clinical cardiology.
[57] K. Swedberg,et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.
[58] J. Bright,et al. Captopril provides sustained hemodynamic benefits in dogs with experimentally induced mitral regurgitation. , 1990, Veterinary surgery : VS.
[59] F. Smith,et al. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. , 1976, The Journal of clinical investigation.
[60] M. Danhof,et al. Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned? , 2015, Reviews of physiology, biochemistry and pharmacology.
[61] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[62] E. Pesavento. What Have We Learned ? , 2006 .
[63] H. Pedersen,et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. , 2002, Journal of veterinary internal medicine.
[64] G. Sanz,et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. , 2000, European heart journal.
[65] K. Swedberg,et al. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. , 1999, European heart journal.